BIOBio-Rad Laboratories, Inc.
Is the price fair?
A demanding price: at the top of its own P/E range and rich vs its sector.
Priced for ~10% a year FCF growth. Moderate growth expectations are priced in.
Expensive vs its own history: P/E 46.3 vs a 10.5 median over 25 quarters (+341% vs median).
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What BIO's price assumes
Bio-Rad Laboratories, Inc. trades at 46.3× earnings against 28.1× for the median Medical Devices name, more expensive than its own group.
Trailing P/E · Medical Devices median 28.1 · 1.65× the median: the market pays up for this one
- Price / sales
- 3.68
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 3.7%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +9.6%
Growth the price implies · The price pays for +9.6% free cash flow growth a year for a decade; the business has delivered +32% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.33
- EV / EBIToperating margin 2.1%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 3.37
- Healthcare median P/E503 names
- 27.9
- Medical Devices median P/E64 names
- 28.1
- Free cash flow, trailing twelve months
- $353M
- Market capitalisation25.8 million shares, counted Jul 30, 2026
- $9.53B
- 3-year revenue growth
- −2.2%
- 3-year free cash flow growth
- +32%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 46.3× today against a 10.5× median |
| 52-week range | $241.71 – $390.31 |
| Today | $370.14 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.